Information Provided By: 
Fly News Breaks for September 7, 2018
PTLA
Sep 7, 2018 | 10:44 EDT
Citi analyst Yigal Nochomovitz said the resignation of Portola Pharmaceuticals' CCO is a "clear positive" and is not much of a surprise given his lack of experience in commercial operations. The analyst believes Portola can now substantially re-shape top-level management with a new COO with the right operational experience ahead of both the Andexxa and Bevyxxa launches. Norchomovitz rates Portola Pharmaceuticals a Buy with a $50 price target.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
